The potential mechanisms of combination therapy include reprogramming of the TME (such as a significant increase in the number of tumor-infiltrating CTLs, and upregulation of PD-L1 and PD-1 expression following VEGFR-2 blockade 188. The gene discussed is PDCD1; the disease is neoplasm.